IPP Bureau
Govt. issues draft amendment to remove cough syrups from Schedule K
By IPP Bureau - January 01, 2026
Once finalized, cough syrups will no longer be available for over-the-counter sale
China’s top court backs Novo Nordisk, upholds semaglutide patent in landmark IP ruling
By IPP Bureau - January 01, 2026
The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
Rare arm cancer defeated: Indore doctors save patient’s arm with complex surgery
By IPP Bureau - January 01, 2026
The surgical team used LD Flap Reconstruction, a specialised technique that rebuilt elbow strength and movement
Savara resubmits FDA application for potential treatment in rare lung disease patients
By IPP Bureau - January 01, 2026
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
Ultragenyx’s Setrusumab falls short in Phase 3 osteogenesis imperfecta trials
By IPP Bureau - January 01, 2026
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
Enveric Biosciences bags key US patent for next-gen neuropsychiatric drugs
By IPP Bureau - January 01, 2026
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
Establishment Labs seeks FDA nod for Motiva breast reconstruction implants
By IPP Bureau - January 01, 2026
Motiva, SmoothSilk, Round and Ergonomix implants represent the latest in plastic surgery innovation
WORK Medical scores regulatory approval for AI-powered blood analyzer
By IPP Bureau - January 01, 2026
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
SOFIE Biosciences doses first patient in Phase 3 trial of novel cancer imaging agent
By IPP Bureau - January 01, 2026
The study will run across 18 sites and enroll roughly 200 patients over 24 months
StimLabs secures FDA nod for groundbreaking human umbilical cord-derived device
By IPP Bureau - January 01, 2026
Theracor is derived from human umbilical cord extracellular matrix (ECM) and is designed to cover, protect, and maintain a moist wound environment
Wockhardt’s WCK 5222 earns accelerated review from European Medicines Agency
By IPP Bureau - January 01, 2026
The accelerated review covers WCK 5222 for multiple critical infections
Johnson & Johnson completes $3.05 billion acquisition of Halda Therapeutics
By IPP Bureau - January 01, 2026
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Co-Diagnostics scores major IP win in Australia with first patent for PCR platform
By IPP Bureau - January 01, 2026
The Co-Dx PCR platform is designed to deliver gold-standard PCR accuracy in a compact, user-friendly device suitable for decentralized testing environments
HUTCHMED’s Fanregratinib gains priority review in China for aggressive liver cancer
By IPP Bureau - January 01, 2026
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
Sinopia Biosciences scores NIH grant to supercharge AI-driven drug discovery
By IPP Bureau - December 31, 2025
The funding will accelerate Sinopia’s data-driven drug discovery efforts
